KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Rad Laboratories (BIO) EBIT Margin (2016 - 2026)

Bio-Rad Laboratories has reported EBIT Margin over the past 18 years, most recently at 5.76% for Q1 2026.

  • Quarterly EBIT Margin rose 171.0% to 5.76% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 2.22% through Mar 2026, down 754.0% year-over-year, with the annual reading at 1.83% for FY2025, 865.0% down from the prior year.
  • EBIT Margin was 5.76% for Q1 2026 at Bio-Rad Laboratories, up from 17.15% in the prior quarter.
  • Over five years, EBIT Margin peaked at 20.91% in Q1 2022 and troughed at 17.15% in Q4 2025.
  • The 5-year median for EBIT Margin is 11.83% (2025), against an average of 10.35%.
  • Year-over-year, EBIT Margin skyrocketed 703bps in 2022 and then plummeted -2589bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 16.25% in 2022, then decreased by -14bps to 13.99% in 2023, then crashed by -38bps to 8.73% in 2024, then tumbled by -296bps to 17.15% in 2025, then skyrocketed by 134bps to 5.76% in 2026.
  • Per Business Quant, the three most recent readings for BIO's EBIT Margin are 5.76% (Q1 2026), 17.15% (Q4 2025), and 10.0% (Q3 2025).